- Home
- ELVA vs NMRA Comparison
ELVA vs NMRA Comparison
Compare ELVA & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- NMRA
- Stock Information
- Founded
- ELVA 1996
- NMRA 2019
- Country
- ELVA Canada
- NMRA United States
- Employees
- ELVA N/A
- NMRA N/A
- Industry
- ELVA
- NMRA
- Sector
- ELVA
- NMRA
- Exchange
- ELVA Nasdaq
- NMRA Nasdaq
- Market Cap
- ELVA 125.5M
- NMRA 121.0M
- IPO Year
- ELVA N/A
- NMRA 2023
- Fundamental
- Price
- ELVA $3.69
- NMRA $2.00
- Analyst Decision
- ELVA Strong Buy
- NMRA Buy
- Analyst Count
- ELVA 5
- NMRA 8
- Target Price
- ELVA $6.10
- NMRA $7.14
- AVG Volume (30 Days)
- ELVA 85.0K
- NMRA 2.1M
- Earning Date
- ELVA 08-12-2025
- NMRA 08-05-2025
- Dividend Yield
- ELVA N/A
- NMRA N/A
- EPS Growth
- ELVA N/A
- NMRA N/A
- EPS
- ELVA N/A
- NMRA N/A
- Revenue
- ELVA $48,016,000.00
- NMRA N/A
- Revenue This Year
- ELVA $55.29
- NMRA N/A
- Revenue Next Year
- ELVA $63.69
- NMRA N/A
- P/E Ratio
- ELVA N/A
- NMRA N/A
- Revenue Growth
- ELVA N/A
- NMRA N/A
- 52 Week Low
- ELVA $1.67
- NMRA $0.61
- 52 Week High
- ELVA $4.07
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- ELVA 61.07
- NMRA 84.53
- Support Level
- ELVA $3.71
- NMRA $0.72
- Resistance Level
- ELVA $4.07
- NMRA $1.41
- Average True Range (ATR)
- ELVA 0.20
- NMRA 0.18
- MACD
- ELVA 0.03
- NMRA 0.09
- Stochastic Oscillator
- ELVA 68.93
- NMRA 96.91
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.